Atyr PHARMA (NASDAQ:ATYR) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Atyr PHARMA’s Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.89) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.22) EPS, […]
Leerink Partnrs upgraded shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Atyr PHARMA’s Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.89) EPS, Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.22) EPS, […]
